Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics

Patent pools for second and third-line Fixed Dose Combination (FDC) antiretroviral drugs (ARVs) should not be delayed as they are instrumental to urgent public health needs in the under-served markets. Nonetheless, multinational originator companies still seem to perceive patent pooling for ARVs as...

Descripción completa

Detalles Bibliográficos
Autores principales: Dionisio, Daniele, Racalbuto, Vincenzo, Messeri, Daniela
Formato: Texto
Lenguaje:English
Publicado: Bentham Open 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831190/
https://www.ncbi.nlm.nih.gov/pubmed/20200604
http://dx.doi.org/10.2174/1874613601004020070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831190/
https://www.ncbi.nlm.nih.gov/pubmed/20200604
http://dx.doi.org/10.2174/1874613601004020070

Ejemplares similares